A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 30 Jan 2017 Status changed from active, no longer recruiting to completed.
- 10 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 10 Dec 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.